DalsnaFinance

i-Lumen Scientific Announces First U.S. Patient Randomized in i-SIGHT2 Pivotal Study Evaluating Noninvasive Bioelectric Therapy for Intermediate to Advanced Dry AMD

Markets PR Newswire By PR Newswire 21 Jul 2026 13:00 1 min read
i-Lumen Scientific Announces First U.S. Patient Randomized in i-SIGHT2 Pivotal Study Evaluating Noninvasive Bioelectric Therapy for Intermediate to Advanced Dry AMD

Milestone initiates U.S. participation in pivotal clinical trial of the i-Lumen AMD System for patients with intermediate to advanced dry age-related macular degeneration BLOOMINGTON, Minn., July 21, 2026 /PRNewswire/ -- i-Lumen Scientific, Inc., a clinical-stage medical technology...

Milestone initiates U.S. participation in pivotal clinical trial of the i-Lumen AMD System for patients with intermediate to advanced dry age-related macular degeneration BLOOMINGTON, Minn., July 21, 2026 /PRNewswire/ -- i-Lumen Scientific, Inc., a clinical-stage medical technology...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.